GTx Closer To Filing NDA For Acapodene With Promising Phase III Results
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Reduced vertebral fracture risk means the selective androgen receptor modulator could offer median survival improvement
You may also be interested in...
GTx Files Toremifene For Prostate Cancer-Related Bone Loss
GTx is looking to be first to market with a treatment for prostate cancer patients that helps prevent common and debilitating fractures caused by androgen deprivation therapy.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.